Sector News

Sanofi, Gilead said to be eyeing $10B deal for Tesaro

June 13, 2017
Life sciences

Earlier this month, industry watchers questioned who could swallow the reportedly on-the-block Tesaro and its $7.5 billion-plus market cap. Now, though, it seems a pair of M&A-starved drugmakers may be interested in trying.

Sanofi—whose recent attempts at big M&A have been frustrated in very public fashion—is reportedly eyeing the Massachusetts biotech, StreetInsider reports. Unfortunately for the French drugmaker, though, it may already have competition. At least one other suitor is involved, too, and SI says it is “likely” Gilead Sciences.

Whoever can land a Tesaro buy will gain access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer. The med rolled out this year after winning a March approval, and it launched with a $118,000 price tag that undercut rivals Lynparza from AstraZeneca and Rubraca from Clovis Oncology.

And Sanofi, which has already tried—and failed—to nab one PARP product, clearly finds the space attractive. It mounted a hostile takeover of California’s Medivation last year, only to see Pfizer eventually swoop in and grab its prize for a cool $14 million. (Later in the year, an attempt to buy Switerzerland’s Actelion—which ultimately structured a newfangled deal with Johnson and Johnson—went similarly.)

Gilead, though, has also said it’s planning to hunt for cancer deals—and that with hepatitis C sales freefalling, it’ll be relying on said deals for growth. The Big Biotech has a new pickup scout in place, too—it hired former Novartis exec Alessandro Riva in January—to make sure the company gets the job done.

One thing is clear: Whichever company does intend to take Tesaro home is going to have to pay up. According to StreetInsider’s source, a takeover of Tesaro would value the company at around $10 billion, or $185 per share.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

July 14, 2024

Flagship raises $3.6B for biotech investing

Life sciences

Flagship Pioneering said Wednesday that it’s added another $3.6 billion to its capital base, bringing the total raised since 2021 to $6.4 billion. Meanwhile, Flagship announced more than a dozen promotions and new hires in its leadership ranks. The changes include the promotions of Lovisa Afzelius and Paul Biondi to general partner and the addition of Dina Ciarimboli as general counsel and executive partner.

July 14, 2024

Mikael Dolsten set to leave Pfizer, sparking search for CSO successor

Life sciences

After 15 years at Pfizer, including a career-defining pandemic period, the chief scientific officer will leave the Big Pharma once the drugmaker finds his successor. Dolsten joined Pfizer when the company closed a megamerger with Wyeth in 2009. Pfizer made Dolsten president of worldwide R&D the following year. The executive has stayed at the top of Pfizer’s R&D tree ever since.

July 14, 2024

CDMO Lotte breaks ground on $3.3B production plant in Korea, touts growth goals

Life sciences

Late last week, Lotte Biologics broke ground on its flagship facility at the Songdo Bio Campus in Incheon International City, South Korea. The company is pitching the production effort as a key part of its quest to become one of the top 10 contract development and manufacturing organizations (CDMOs) in the world, Lotte said in a press release.

How can we help you?

We're easy to reach